Current Report Filing (8-k)
June 05 2019 - 04:09PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 5, 2019
Agios Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-36014
|
|
26-0662915
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
88 Sidney Street, Cambridge, MA
|
|
02139
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617)
649-8600
(Former Name
or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, Par Value $0.001 per share
|
|
AGIO
|
|
Nasdaq Global Select Market
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the
Securities Act of 1933 (§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.
|
On June 5, 2019, Scott Biller, Ph.D., the Chief Scientific Officer of Agios
Pharmaceuticals, Inc. (the Company) and a named executive officer of the Company, notified the Company of his intention to resign from his current role effective December 31, 2019. Following his resignation,
Dr. Biller will serve as a strategic advisor for the Company through the end of 2020, for which he will be compensated at fifty percent (50%) of his 2019 cash compensation (including salary and target bonus) as described in the Companys
Proxy Statement for the 2019 Annual Meeting of Stockholders.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
AGIOS PHARMACEUTICALS, INC.
|
|
|
|
|
Date: June 5, 2019
|
|
|
|
By:
|
|
/s/ Jacqualyn A. Fouse
|
|
|
|
|
|
|
Jacqualyn A. Fouse, Ph.D.
|
|
|
|
|
|
|
Chief Executive Officer
|
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Feb 2024 to Mar 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2023 to Mar 2024